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Abstract 
Background: Ingenol-mebutate has been used for the treatment of actinic keratosis. It has been shown that inge-
nol-mebutate inhibits the growth of cancer cells or induces tumor cell death through pro-apoptotic effects. Keloids 
are benign skin tumours and are the effect of a deregulated wound-healing process in genetically predisposed 
patients. Increased cell proliferation, which accounts for the progressive and hypertrophic nature of keloids, correlates 
with the failure of apoptosis and plays a role in the process of pathological scarring. Keloid cells show a mutated p53 
gene resulting in functionally inactive p53 protein which cannot control genomic integrity. They tend to escape from 
apoptosis which leads to keloid development by means of accumulation of continuously proliferating cells. Currently, 
the treatment of keloids remains a challenge for high recurrence rates. However, the design and the development of 
pro-apoptotic therapeutic strategies would be beneficial to keloids treatment.
Case presentation: A 55-year-old caucasian woman presented recurrent keloids on a presternal scar. Standard surgi-
cal intervention was used to treat the scar. However, this was unsuccessful and a year later the patient sought treat-
ment again, but only by alternative means as the patient refused further surgical intervention. Consequently, based 
on past research and experience, the authors attempted to treat these lesions with ingenol mebutate gel, due to the 
pro-apoptotic effects.
Conclusion: After 1 month, there was a clinical resolution of lesions, with a slightly squamous, post-inflammatory 
erythema. A cutaneous biopsy proved the absence of residual keloids and deregulated expression of molecular 
markers. The last follow-up of the patient, 1 year after treatment, showed that the patient was still free of keloids 
recurrence.
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Background
Ingenol-mebutate has been used in recent treatments of 
actinic keratosis (also called solar keratosis or dyskerato-
sis). Ingenol mebutate is a diterpene ester, hydrophobic, 
isolated from the plant Euphorbia peplum, which at con-
centrations higher than 200 μmol/L, diffuses through the 
skin within a few hours after application, concentrating 
mainly in the epidermis and into the dermis to a lesser 
extent. The exact mechanism of action is unknown. It is 
believed that the active ingredient has pleiotropic effects 
inhibiting the growth of cancer cells or induces tumor 
cell death through multiple mechanisms. ‘In vivo and 
in vitro’ models have shown a dual mechanism of action 
[1]: direct cell death is quickly expressed in tumoral 
keratinocytes and performs its function with the entry 
of the molecule into the cell by lysis of pinosomi. Stud-
ies with immuno-fluorescence have shown, within the 
cell, in response to ingenol-3-angelate, PKC-δ (protein 
kinase C-delta) translocation from the cytosol to the 
peri-nuclear membrane, [2]. The disruption of the plasma 
membrane, as demonstrated by electron microscopy, 
leads to an increase in the intracellular concentration of 
calcium ions, which, for the gradient, penetrate into the 
mitochondria causing mitochondrial swelling and lysis 
[2]. The lack of production of ATP, following the destruc-
tion of mitochondria, determines cell necrosis. Beside 
the pro-apoptotic effects, immuno-stimulant effects are 
documented due to an increased release of chemokines 
by activated T cells, local infiltration of neutrophils with 
increased antibody-dependent cytotoxicity, and finally, 
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the development of specific autoimmune responses of 
CD8 (+) T cells. The inflammatory reaction determined 
in the dermis, induces an activation and infiltration of 
immuno-competent cells as neutrophils, with primary 
necrosis of tumor cells. It has been demonstrated, in 
fact, that the exposure of human keratinocytes in vitro to 
ingenol mebutate, causes the release of chemokines and 
pro-inflammatory cytokine TNF-α (Tumor necrosis fac-
tor-alpha), leading to neutrophil activation mediated by 
PKC [2].
Direct pro-apoptotic effects of this drug have been 
demonstrated in several malignant cells, including 
melanoma cell lines [3]. Topical application of ingenol 
mebutate was revealed as being effective for human and 
murine melanoma in mouse models. Further preclini-
cal murine modeling has demonstrated that, through 
P-glycoprotein-mediated absorptive drug transport, 
ingenol mebutate can pass the stratum corneum barrier 
and penetrate to exert its pharmacological effects in the 
dermis and hypodermis [4]. Ingenol mebutate treatment 
also reduced the number of mutant p53 keratinocyte 
patches by about 70 %. No published data are available on 
a potential effect of ingenol mebutate on keloids [5].
Keloids are benign skin tumours and are the effect of 
a deregulated wound-healing process in genetically pre-
disposed patients. They are characterized by formation of 
excess scar tissue beyond the boundaries of the wound. 
Keloids are often confused with hypertrophic scars 
because of an apparent lack of morphologic differences.
We already found the extent of apoptosis by DNA 
fragmentation and MTT assays, propidium iodide stain-
ing, p53 expression, and subcellular distribution [6–9]. 
We also found that selenocystine, a nutritionally avail-
able seleno-amino acid, was identified for the first time 
as a novel agent with anti proliferative activity on human 
keloids. The 20  μM concentration after 48  h treatment 
used here was the most effective to reduce keloid fibro-
blast growth [10].
In a previous research [8], we addressed the mecha-
nisms by which keloids, in contrast to hypertrophic scars, 
escape from apoptosis. Our data demonstrated that p53 
under-expression, due to the sequence mutations, in 
concert with ΔNp63 activation is the central mechanism 
involved in keloid proliferation and explains the aberrant 
growth. ΔNp63 works as a dominant-negative protein 
upon p53 preventing the latter from activating its target 
genes in apoptosis process suppression of apoptosis con-
tribute to keloid development by means of accumulation 
of continuously proliferating cells whereas the disruption 
or elimination of genetically altered cells might decrease 
tumor potential. We also showed that p53 and ΔΝp63 
deregulated expression can present prognostic relevance 
as differential apoptosis markers in human keloids.
Here, we describe a case report of a woman with a 
large keloid on a presternal scar (Additional file  1). The 
original treatment was unsuccessful the patient categori-
cally refused further surgical intervention. Consequently, 
based on past research, we decided the best option was to 
treat such keloid lesions, for the first time, with ingenol 
mebutate gel. We also assessed ΔΝp63 and p53 altered 
expression in a cutaneous biopsy from the patient before 
and 1 month after treatment.
Consent
Written informed consent was obtained from the patient 
for publication of this case report and any accompany-
ing images. A copy of the written consent is available for 
review by the Editor-in-Chief of this journal
We obtained ethics approval for our study from the 
ethics committee of the University of Naples II, Italy. All 
procedures used in the study were in accordance with the 
current international guidelines, with the standards on 
human experimentation of the Ethics Committee of the 
University of Naples II, Italy, and with the Helsinki Decla-
ration of 1975, revised in 1983.
Case presentation
Initial presentation and diagnostics
A 55-year-old caucasian woman presented with biopsy 
proven recurrent keloids on a presternal scar, subsequent 
to intervention of sternotomy, located from manubrio-
sternal joint to xiphoid appendix.
The patient had been subjected to sternotomy to treat a 
severe form of heart valve insufficiency in the year before 
the treatment. The wounds caused by this surgery, for no 
apparent underlying cause, evolved spontaneously in a 
tissue hypertrophy with a violent inflammation and with 
symptoms of itching and burning. Within 2 months the 
scar markedly increased, overflowing from the edges of 
the wound.
As the patient refused to undergo further surgery, we 
carried out three intralesional fortnightly injections of 
triamcinolone acetonide 40 mg/ml, which led initial atro-
phy and telangiectasia, without reducing the symptoms.
Before starting treatment, the clinical appearance was 
confirmed by taking a skin biopsy punch with 4  mm to 
presternal region. The diagnosis of a keloid was rather 
simple and consisted of a simple examination of the 
lesion and a histological examination, which confirmed 
the diagnosis of keloid. We also assessed ΔΝp63 and 
p53 altered expression which confirmed the diagnosis of 
keloids (data not shown).
Treatment
Since the previous treatment was unsuccessful and the 
patient refused any further surgical intervention, the 
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authors decided to attempt to treat the lesions with 
500 µg/g gel of ingenol mebutate (everyday applications 
for 2 days), based on in  vitro data on keloids cell lines 
[5–9].
The exact mechanism of action of ingenol mebutate is 
not clear yet, but it has proven to be effective in remov-
ing actinic keratosis. After the application of ingenol 
mebutate, the majority of patients (over 95  %) reported 
one or more skin reactions at the local level such as itch-
ing and burning caused by a large inflammation, which is 
resolved within 30 days with a frequent resolution of the 
underlying disease. Treatment with ingenol mebutate has 
no contraindications except hypersensitivity to the active 
substance or to any of the excipients.
Here, ingenol mebutate gel was applied the first and 
the second day. The patient was examined at o, 10, 15, 
20, 30 and 50 days after the application performed on the 
lesion area (Fig. 1a–f). On the day 10 of the application, 
a moderately crusting and oozing reaction was observed. 
According to the severity scale of local skin responses, 
which are the most common adverse effects of ingenol 
mebutate therapy [11], the composite score was 14/24: 
erythema: 4, flaking or scaling: 2, crusting: 4, swelling: 
3, vesiculation or postulation:  1, erosion or ulceration: 
0. In contrast, before treatment, the composite score 
was 12/24: erythema: 6, flaking or scaling: 0, crusting: 
0, swelling: 6, vesiculation or postulation:  0, erosion or 
ulceration: 0. One month later, there was a clinical reso-
lution of lesions, with a slightly squamous, post-inflam-
matory erythema (Fig. 1f ).
Real‑time assay
A second cutaneous biopsy, 1 month after treatment, 
proved the absence of residual keloids molecular mark-
ers. Real time assay was performed on the biopsy after 
treatment showing that ΔΝp63 and p53 was expressed 
almost as well as in hypertrophic scar and normal fibro-
blasts (Fig. 2). Control patient was a sex and age matched 
healthy patient. Usually, in keloid fibroblasts, ΔNp63 is 
overexpressed while p53 is under-expressed compared to 
normal fibroblasts [8].
All results shown are mean ± SD of at least three sepa-
rate experiments, measuring each parameter by triplicate 
(n = 3). Statistical significant differences were tested by 
one way analysis of variance (ANOVA), and, when the 
F value was significant, by Student-Newman-Keul’s test. 
P value less than 0.05 (*) was considered statistically 
significant.
Follow‑up
The local tolerance of the treatment was acceptable for 
the patient and no systemic signs were observed. After 
6  months of follow-up, the patient was still free from 
recidivant keloid scar.
The last follow-up of the patient, one year after treat-
ment has not shown any clinical element that would sug-
gest a flare up of the keloid disease. We have not taken 
a further skin biopsy for lack of clinical expression of 
keloid. At the present, the patient doesn’t display any 
keloid scar.
Fig. 1 Patient‘s examination at 0 (a), 10 (b), 15 (c), 20 (d) 30 (e) and 
50 (f) days after the ingenol-mebutate application performed on the 
lesion area
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Future follow-up will be mainly clinical, but we plan 
also to perform more biopsies to confirm the absence of 
keloid.
Discussion
Keloids are a grave psychological and physical dermato-
logical condition for patients.
Keloid scarring is a raised scar which forms by expand-
ing beyond the boundaries of the original lesion [12]. 
The most important histological manifestation of keloids 
is the overgrowth of atypical fibroblasts with excessive 
amassing of extra-cellular matrix components, particu-
larly collagen, proteoglycans fibronectin and elastin, [13]. 
Keloid scar formation, differing from normal wound 
healing, starts with abnormal tissue growth in the der-
mal lesion extending beyond the borders of the origi-
nal wound [13]. Suppression of apoptosis contributes to 
keloid development by means of accumulation of contin-
uously proliferating cells, which account for the progres-
sive and hypertrophic nature of keloids.
Despite the several studies performed on molecular 
mechanisms and treatment of keloids, the exact patho-
genesis of such disease remains unknown and this makes 
therapies more problematic.
Current common treatments for keloids are often a 
combination of excision followed by a reconstructive 
surgical procedure [14]. Glucocorticoids or 5-fluoroura-
cil injections followed by compression therapy such as 
silicone sheets are frequently employed. Nonetheless, 
recurrence remains between 45 and 100  %. Therefore, 
treatment of keloids is still a challenge. Surgery is the 
gold standard to treat any size of keloid, as it reduces the 
mass of the lesion. More strategies to prevent post-exci-
sion recurrence of keloids have been mentioned includ-
ing silicone occlusive dressing, mechanical compression, 
radiation, cryosurgery, topical imiquimod application, 
bleomycin, intra-lesional injections of steroids, 5-fluoro-
uracil as well as interferon alpha, -beta and -gamma [15].
In general, there is adequate evidence that several ther-
apies have a synergistic effect when used together. Even 
if with limitations, significant improvement is possible 
with the available treatments. However, management of 
keloids remains difficult for high recurrence rates.
Lately, pro-apoptotic effects of ingenol-mebutate have 
been demonstrated [3]. Due to such effects, topical appli-
cation of ingenol mebutate was revealed as being effec-
tive in humans for the treatment of precancerous skin; 
therefore we attempted to treat with ingenol mebutate 
the lesions from a patient showing recurrent keloids.
Our case report suggests that in some selected patients 
with keloids, ingenol mebutate could be considered as 
an alternative treatment. It could present the advan-
tage, over usual treatment, that does not display poten-
tial recurrence or side effects, indeed, cutaneous adverse 
effects are shorter in duration with ingenol mebutate. 
The local tolerance of the treatment was acceptable 
for the patient, which after 1 year is still free of keloids. 
Additionally, the cutaneous biopsy proved the absence of 
residual keloids molecular markers as ΔΝp63 and p53.
Conclusion
Ingenol mebutate could be considered as an alterna-
tive treatment option for keloids in patients, after other 
therapies have failed. Future studies and large number of 
samples are warranted to assess if ingenol mebutate is a 
suitable treatment for patients with keloids and to clarify 
the molecular mechanisms underlying the positive out-
come of such treatment.
Abbreviations
p53 protein: Tumor suppressor p53; ΔNp63 protein: Isoform of the p53 
homologue p63, which lacks an amino-terminal transactivation domain and 
antagonizes the induction of the gene expression by Deltap63; PKC-δ protein: 
Protein kinase C-delta; ATP: Adenosine triphosphate, coenzyme used as an 
energy carrier in the cells of all known organisms; CD8 (+) T cells: T cell with 
CD8 receptor that recognizes antigens on the surface of a virus-infected 
cell and binds to the infected cell and kill it; TNF-α: Tumor necrosis factor-
alpha; PKC: Protein kinase C; MTT assays: Colorimetric assay for assessing cell 
metabolic activity. NAD(P)H-dependent cellular oxidoreductase enzymes may, 
under defined conditions, reflect the number of viable cells present. These 
enzymes are capable of reducing the tetrazolium dye MTT 3-(4,5-dimethylth-
iazol-2-yl)-2,5-diphenyltetrazolium bromide to its insoluble formazan, which 
has a purple color.
Additional files
Additional file 1: Care check list.
Fig. 2 p53 and Δp63 expression level from a cutaneous biopsy, in 
the keloid case patient one month after treatment with ingenol-
mebutate and in a control case
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